For comparison, PNH and IgAN affect around 10-20 and 25 people per million, respectively. Sales of Fabhalta were $22 million in the second quarter, with what Novartis has called "encouraging early ...

Fabhalta is already approved in the US, EU, and Japan as a therapy for paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder, and is the first oral alternative to injectable or infused ...

The drug was approved by the agency in 2023 as a treatment for paroxysmal nocturnal hemoglobinuria, winning the title of the first oral monotherapy approved for the rare blood disorder.

SAR-443809 is under clinical development by Sanofi and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have ...